Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis
NCT05988437 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2023-09-28
Summary
Hypersensitivity pneumonitis (HP) is a diffuse infiltrative pneumonitis (DIP) of immuno-allergic origin, caused by exposure to one or more antigenic substances of organic origin, in genetically predisposed individuals. It can take a fibrosing form, eventually leading to chronic respiratory failure. Diagnosis is based on a combination of clinical, biological, CT scan and histological evidence, and is made during multidisciplinary discussions (MDD) of diffuse interstitial lung disease.
The antigens responsible, of domestic or professional origin, may be micro-organisms, animal proteins or chemical agents. However, the antigen remains unknown in almost 50% of cases. Lack of antigen identification is an independent risk factor for death in patients with fibrosing HP. In fibrosing forms, corticosteroid therapy does not appear to improve functional prognosis, and ninedanib, an antifibrosing treatment offered in progressive forms, only slows functional decline. Identifying the causative antigen is therefore an essential element in the overall management of these patients, with the aim of implementing avoidance measures. A medical exposure questionnaire has been translated into French to help physicians identify the antigen.
The serum precipitin assay is a tool developed to help identify sensitization to an antigen. It is all the more useful when investigations are targeted at the patient's suspected exposure. However, their sensitivity and specificity are variable.
The activity of the indoor environment medical advisor (CMEI) has developed in the care of patients with chronic respiratory or allergic pathologies. Their role is to carry out an audit of the dwelling, take environmental measurements to assess the health risk, inform patients about appropriate eviction measures and, in some cases, refer patients to organizations specializing in home improvement.
The CMEI visits the patient's home. The environmental audit includes a rigorous macroscopic examination and microbiological swabs of visible anomalies. The CMEI can also supplement its analysis with electrostatic dust collectors, which are left in the home for 4 weeks, enabling both qualitative and quantitative characterization of antigens.
To date, no study has prospectively evaluated the contribution of CMEI to antigen identification in patients with fibrosing HP. At the Nantes University Hospital and Angers University Hospital, the environmental audit carried out by the CMEI is an integral part of routine patient management in the event of a HP diagnosis.
The main objective of this study is to measure the diagnostic contribution of the indoor environment medical advisor in the identification of antigens responsible for respiratory pathology in patients with fibrosing HP.
Conditions
- Hypersensitivity Pneumonitis
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Principal Investigators
-
Stéphanie DIROU, PH · Nantes University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-12
- Primary Completion
- 2026-06-12
- Completion
- 2026-06-12
Countries
- France
Study Locations
More Related Trials
-
Pulmonary Fibrosis and Telomerase Mutation Study
NCT01501578 ·Status: COMPLETED
-
Emphysema and FLNA Mutation (E-FLNA)
NCT05550844 ·Status: COMPLETED
-
Interstitial Lung Disease Exacerbations Study
NCT06685874 ·Status: ACTIVE_NOT_RECRUITING
-
Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases
NCT01600378 ·Status: RECRUITING
-
Pulmonary Care and Research Collaborative Patient Registry
NCT05445817 ·Status: UNKNOWN
-
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
NCT02594059 ·Status: COMPLETED ·Phase: NA
-
Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis
NCT03171870 ·Status: UNKNOWN ·Phase: NA
-
Mechanisms of Familial Pulmonary Fibrosis
NCT03437486 ·Status: RECRUITING
-
Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis
NCT03898284 ·Status: COMPLETED
-
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
NCT00470327 ·Status: RECRUITING
-
68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis
NCT01321996 ·Status: TERMINATED ·Phase: PHASE4
-
Dyspnea and Idiopathic Pulmonary Fibrosis
NCT04864990 ·Status: COMPLETED
-
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives
NCT06036719 ·Status: RECRUITING
-
The Clinical Course of Interstitial Pneumonia With Autoimmune Features
NCT03950583 ·Status: COMPLETED
-
RaDiCo PID Cohort (RaDiCo-ILD Cohort in English)
NCT04238871 ·Status: TERMINATED
-
Digital Modeling of Thoracic CT and Pulmonary Fibrosis
NCT06618924 ·Status: ACTIVE_NOT_RECRUITING
-
Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT
NCT02468609 ·Status: UNKNOWN ·Phase: NA
-
Biological Determinants of Sputum Rheology in Chronic Airway Diseases
NCT04081740 ·Status: COMPLETED
-
Prognostic Features for Mortality in Young Adults With Pneumonia
NCT00845312 ·Status: COMPLETED
-
Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery
NCT00558350 ·Status: COMPLETED
-
Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema
NCT00700934 ·Status: UNKNOWN
-
Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study
NCT03836417 ·Status: COMPLETED
-
Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung Function
NCT01651507 ·Status: COMPLETED
-
Ongoing Monitoring of Vital Signs in Patients With Idiopathic Pulmonary Fibrosis Before and After Acute Exacerbation.
NCT06445686 ·Status: RECRUITING
-
A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
NCT03261037 ·Status: COMPLETED ·Phase: NA